Association of caffeine consumption with memory deficits and cerebrospinal fluid biomarkers in Mild Cognitive Impairment and Alzheimer's Disease: a BALTAZAR cohort study

We investigated the link between habitual caffeine intake with memory deficits and CSF AD biomarkers in Mild cognitive impairment (MCI) and Alzheimer s Disease (AD) patients. MCI (N=147) and AD (N=116) patients of the BALTAZAR longitudinal cohort reported their caffeine intake using a dedicated survey and were followed-up for 3 years. Associations of caffeine consumption with cognition, MMSE decline and CSF biomarkers (Tau, pTau181, Ab1-42, Ab1-40) were analyzed using logistic and ANCOVA models. Adjusted on APOE4, age, sex, education level and tobacco, lower caffeine consumption was associated with higher risk to be amnestic (OR: 2.49 [95%CI: 1.13 to 5.46]; p=0.023) and lower CSF Ab1-42 (p=0.047), Ab1-42/ A1-40 (p=0.040) and Ab1-42/pTau (p=0.020) in the whole cohort and a faster MMSE decline in amnestic MCI (p=0.024). Data supports the beneficial effect of caffeine consumption to memory decline and CSF amyloid markers in MCI and AD patients.